1282514-64-0

Basic information

• Product Name: 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester
• Synonyms: 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester;ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate;Ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1
• CAS NO: 1282514-64-0
• Molecular Formula: C26H31N7O3
• Molecular Weight: 489.58
• Mol File: 1282514-64-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester(1282514-64-0)
• EPA Substance Registry System: 1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]iMidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester(1282514-64-0)

Safety Data

• Hazardous Substances Data: 1282514-64-0(Hazardous Substances Data)

Usage

Molecular Structure

1H-Pyrazole-1-acetic acid, 4-[5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-diMethyl-, ethyl ester has a complex molecular structure that includes a pyrazole acetic acid core, a dihydro-2, an α,α-diMethyl group, and an ethyl ester functional group.

Pyrazole Acetic Acid Core

The compound contains a 1H-pyrazole-1-acetic acid core, which is a five-membered heterocyclic ring system with one nitrogen atom and one oxygen atom.

Dihydro-2

The compound features a dihydro-2 group, which is a saturated hydrocarbon group resulting from the addition of hydrogen to a double bond in the 2-position of the molecule.

α,α-DiMethyl Group

The compound has an α,α-diMethyl group, which consists of two methyl groups attached to the same carbon atom, contributing to the molecular complexity and potentially affecting its pharmacological properties.

Ethyl Ester Functional Group

The presence of an ethyl ester functional group in the compound suggests that it may have ester-based properties and reactivity, which could be relevant for its potential applications in medicinal chemistry.

Pharmacological and Biological Activities

The complex molecular structure of the compound suggests that it may have potential pharmacological and biological activities, although further research and analysis are needed to fully understand these properties.

Upstream product

• 1282514-63-9 9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282512-48-4 taselisib 
• 1282516-74-8 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d]-[1,4]oxazepine-2-carboxylic acid 
• 635702-31-7 4-bromo-2-fluoro-N-hydroxybenzimidamide 
• 1040377-17-0 ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate 
• 851975-10-5 2-methyl-2-(1H-pyrazol-1-yl)propanoic acid 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 1401305-30-3 1-isopropyl-3-methyl-1H-1,2,4-triazole 
• 1282516-77-1 2-(2-(4-bromo-2-fluorophenyl)-4-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-1H-imidazol-1-yl)ethanol 
• 1282516-76-0 5-(2-(4-bromo-2-fluorophenyl)-1H-imidazol-4-yl)-1-isopropyl-3-methyl-1H-1,2,4-triazole 
• 1201657-32-0 ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate 
• 600-00-0 ethyl 2-bromoisobutyrate 

Downstream Products

• 1282512-48-4 taselisib 
• 1282513-03-4 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid 

Relevant articles and documents

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process

A highly efficient and regioselective manufacturing route for the phosphoinositide 3-kinase β-sparing inhibitor taselisib was developed. Highlights of the synthesis include: (1) magnesium-mediated formation of a challenging cyclic amidine; (2) regioselect

MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3 KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER

Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.